Previous 10 | Next 10 |
Psilocybin is the focus of more researchers and more business developers than ever before as study after study demonstrate its range of effectiveness. In fact, to date, over 27,000 scientific articles have been published on psychedelic drugs, with over 1,000 particular...
NeonMind Biosciences ( CSE:NEON)(OTC:NMDBF) is a step closer to bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders. With obesity, for example, worldwide obesity has tripled since 1975, says the World Health Organization. Plus,...
When you take a big picture look at the psychedelics industry, you can easily get starry-eyed: Predictions of $6.85 billion industry by 2027 . Mental health and wellness demands firing up a ready-made market. Support from more and more mainstream educational and institut...
Mental health is on the decline all over the world. In the U.S. for example, the White House noted, “Our country faces an unprecedented mental health crisis among people of all ages. Two out of five adults report symptoms of anxiety or depression. And, Black and Brown communities are...
Today, we conduct our first assessment around Compass Pathways. The company is advancing its lead candidate, which is a psychedelic drug treatment across two indications in mid to late stage development. A full investment analysis follows in the paragraphs below. For further...
NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response...
LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in and attend one-on-one ...
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q4 2021 Earnings Call Feb 24, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q4 2021 Earnings Call Transcript
The following slide deck was published by COMPASS Pathways plc in conjunction with their 2021 Q4 earnings call. For further details see: COMPASS Pathways plc 2021 Q4 - Results - Earnings Call Presentation
COMPASS Pathways plc (CMPS) Q4 2021 Earnings Conference Call February 22, 2022 2:00 AM ET Company Participants Steven Schultz - SVP, IR George Goldsmith - Chairman & CEO Guy Goodwin - Chief Medical Officer Mike Falvey - CFO Conference Call Participants Ritu Baral - Cowen and Company Charl...
News, Short Squeeze, Breakout and More Instantly...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...